Beauty Health Q1 2025 Earnings Report
Key Takeaways
BeautyHealth reported first quarter 2025 results with net sales of $69.6 million, a decrease of 14.5% year-over-year, primarily due to lower delivery system sales. Despite the revenue decline, the company improved its gross margin and adjusted EBITDA, driven by cost efficiencies and a favorable shift towards consumables revenue.
Net sales for Q1 2025 were $69.6 million, a decrease of 14.5% compared to Q1 2024.
Gross margin improved to 69.8% in Q1 2025, up from 59.4% in Q1 2024.
Adjusted EBITDA was $7.3 million in Q1 2025, a significant increase from $0.4 million in Q1 2024.
Consumables net sales remained resilient, growing to $49.4 million in Q1 2025.
Beauty Health
Beauty Health
Beauty Health Revenue by Segment
Beauty Health Revenue by Geographic Location
Forward Guidance
For the second quarter of 2025, the company expects net sales between $71 million and $76 million and adjusted EBITDA between $2 million and $4 million. For the full fiscal year 2025, net sales are projected to be between $270 million and $300 million, with adjusted EBITDA between $15 million and $25 million.
Positive Outlook
- Anticipated growth in consumable net sales.
- Continued focus on expanding profit margins and driving shareholder value.
- Pipeline of impactful product launches and brand initiatives.
- Transitioning China operations to a distributor model to potentially improve efficiency.
- Relocating production to the U.S. to mitigate tariff risk.
Challenges Ahead
- Continued downward pressure on delivery systems net sales.
- Assumes no material deterioration in current general market conditions.
- Assumes no unforeseen circumstances such as foreign currency exchange rates, tariffs, and trade restrictions.
- Excludes any unannounced acquisitions, dispositions or financings.
- Forecasting and quantifying certain amounts for non-GAAP reconciliation is difficult.
Revenue & Expenses
Visualization of income flow from segment revenue to net income